Evidence map›Paper›PMID 37671411›Full record

ArticleACS chemical biology2023

Interface Engineering of Carrier-Protein-Dependent Metabolic Pathways.

Terra Sztain, Joshua C Corpuz, Thomas G Bartholow, Javier O Sanlley Hernandez, Ziran Jiang, Desirae A Mellor, Graham W Heberlig, James J La Clair, J Andrew McCammon, Michael D Burkart

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Terra SztainDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.ORCID 0000-0002-1327-8541
Joshua C CorpuzDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Thomas G BartholowDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Javier O Sanlley HernandezDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Ziran JiangDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Desirae A MellorDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Graham W HeberligDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
James J La ClairDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
J Andrew McCammonDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.ORCID 0000-0003-3065-1456
Michael D BurkartDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.ORCID 0000-0002-4472-2254
University of California San Diego · US

Funding

MOLECULAR BIOPHYSICS TRAINING PROGRAMT32GM008326 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOMIVES, ELIZABETH A. · 1989 to 2020
$7.5M
Protein-Protein Interactions in Natural Product BiosynthesisR01GM095970 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURKART, MICHAEL D. · 2012 to 2025
$5.9M
UCSD Biomedical Scientist Career Development Program in GlycoscienceK12HL141956 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ESKO, JEFFREY D, GODULA, KAMIL · 2018 to 2022
$5.3M
Chemistry-Biology Interfaces at UCSDT32GM146648 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael D. Burkart, Alexis C. Komor · 2022 to 2026
$876k
Targeting protein-protein interactions as drug targetsR21AI156484 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURKART, MICHAEL D. · 2021 to 2022
$434k
Creating natural product diversity via the fabrication of a hybrid fatty acid-nonribosomal peptide synthetaseF31GM137616 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CORPUZ, JOSHUA CATUNGAL · 2021 to 2022
$59k
NHLBI NIH HHS K12 HL141956NIAID NIH HHS R21 AI156484NIGMS NIH HHS F31 GM137616NIGMS NIH HHS R01 GM095970NIGMS NIH HHS T32 GM008326NIGMS NIH HHS T32 GM146648
6 · The paper itself

Abstract

Carrier-protein-dependent metabolic pathways biosynthesize fatty acids, polyketides, and non-ribosomal peptides, producing metabolites with important pharmaceutical, environmental, and industrial properties. Recent findings demonstrate that these pathways rely on selective communication mechanisms involving protein-protein interactions (PPIs) that guide enzyme reactivity and timing. While rational design of these PPIs could enable pathway design and modification, this goal remains a challenge due to the complex nature of protein interfaces. Computational methods offer an encouraging avenue, though many score functions fail to predict experimental observables, leading to low success rates. Here, we improve upon the Rosetta score function, leveraging experimental data through iterative rounds of computational prediction and mutagenesis, to design a hybrid fatty acid-non-ribosomal peptide initiation pathway. By increasing the weight of the electrostatic score term, the computational protocol proved to be more predictive, requiring fewer rounds of iteration to identify mutants with high in vitro activity. This allowed efficient design of new PPIs between a non-ribosomal peptide synthetase adenylation domain, PltF, and a fatty acid synthase acyl carrier protein, AcpP, as validated by activity and structural studies. This method provides a promising platform for customized pathway design, establishing a standard for carrier-protein-dependent pathway engineering through PPI optimization.

Indexed as

Acyl Carrier ProteinCarrier ProteinsExcipientsFatty AcidsFatty Acid SynthasesMetabolic Networks and PathwaysAcyl Carrier ProteinCarrier ProteinsExcipientsFatty AcidsFatty Acid Synthases

Identifiers

PMID37671411
PMCPMC10807135
OpenAlexW4386467083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.